We demonstrate that combination treatment with HER2 targeting monoclonal antibodies Pertuzumab and Trastuzumab cause greater inhibition of NRF2 function and subsequent greater repression of NRF2 dependent antioxidant responses in human ovarian cancer cell lines. This evidence concerns the gene ERBB2 and ovarian cancer.